- Policy
- Concerns about National Bio Committee's foreign pharma exec
- by Lee, Jeong-Hwan Nov 29, 2024 05:54am
- The National Bio Committee, chaired by President Yoon Suk Yeol, is set to launch in December. However, reports indicate that a global pharmaceutical company executive has been included as a committee member, raising concerns. The committee comprises up to 40 members, including the chair, vice-chair, various ministers, and officials from t
- Company
- Sales rights for Viviant·Tuvero·Akarb to be transferred
- by Kim JiEun Nov 28, 2024 05:55am
- Due to changes in sales rights for blockbuster items that are frequently dispensed, the pharmaceutical supply and demand are expected to be affected in the end-of-year period and early 2025. According to the pharmaceutical distributor industry on November 26, several pharmaceutical companies are expected to change their distributors at
- Policy
- KIPO opposes to objections to new drug patent extended cap
- by Lee, Jeong-Hwan Nov 28, 2024 05:55am
- The Korea Research-based Pharma Industry Association (KRPIA) and others have submitted an opinion disagreeing with the proposed legislation that would introduce a maximum cap for terms of patent protection for new drugs. The proposed legislation is intended to facilitate an earlier market launch for Korea-made new drugs. The Korean Intellect
- Policy
- Trial for targeted drug 'VERT-002' for NSCLC begins in KOR
- by Lee, Hye-Kyung Nov 28, 2024 05:55am
- A clinical trial of 'VERT-002,' an innovative targeted treatment for degrading a c-MET gene, will begin in South Korea. C-MET gene is known as one of the cancer-inducing factors of non-small cell lung cancer (NSCLC). On November 27, the Ministry of Food and Drug Safety (MFDS) has granted approval of 'a first-in-human (FIH) multi-center, do
- Policy
- Handok’s thrombocytopenia drug Doptelet approved in KOR
- by Lee, Hye-Kyung Nov 28, 2024 05:54am
- Handok's new rare disease drug ‘Doptelet (avatrombopag)' was approved in Korea on the 26th. The Ministry of Food and Drug Safety approved Doptelet as a treatment for thrombocytopenia for patients with liver disease. Handok is reaping the benefits of forging a strategic partnership with the global biopharmaceutical company Sobi-Handok
- Policy
- Lagevrio prescription age raised from 60 to 70
- by Kang, Shin-Kook Nov 28, 2024 05:54am
- The prescription age for the government-supplied COVID-19 treatment, Lagevrio, will be raised from 60 to 70 from the 27th.&160; According to the Korea Disease Control and Prevention Agency (KCDA), the three COVID-19 drugs (Paxlovid, Lagevrio, Veklury Inj) that were initially supplied by the government, were planned to be included in Korea’s
- Company
- Lilly appoints Stacie Liu to head the CardioMetabolic Health
- by Eo, Yun-Ho Nov 28, 2024 05:54am
- Lilly Korea has named Stacie Liu (37), as the new Senior Director of its CardioMetabolic Health Business Unit On the 1st, Lilly Korea announced that it had appointed Stacie Liu as the Senior Director of its CardioMetabolic Health Business Unit. In this role, Liu will be responsible for setting and executing the business strategy for Li
- Company
- ‘The new ATTR-CM treatment can improve patient survival’
- by Whang, byung-woo Nov 27, 2024 05:50am
- With the possibility for reimbursement coverage for the ultra-rare disease,&160;transthyretin amyloid cardiomyopathy (ATTR-CM) rising, excitement is also rising in the clinical site. Due to the short life expectancy of ATTR-CM - 2-3.5 years after diagnosis &8211; and no clear treatment option available, the benefits of a new treatment optio
- Company
- Active development of new drugs for myasthenia gravis
- by Son, Hyung Min Nov 27, 2024 05:50am
- Competition in the pharmaceutical market is heating up to secure myasthenia gravis indication. UCB's new drug was approved in South Korea, and Janssen finished the phase 3 trial, aiming to acquire regulatory approvals worldwide. In South Korea, Handok seeks to enter the market with its acquired new drug. HanAll Biopharma is conducting a Phase 3
- Company
- 4 of 5 listed pharma companies expand investments
- by Chon, Seung-Hyun Nov 26, 2024 05:54am
- Pharmaceutical companies have significantly expanded their research and development (R&D) investments to discover their next item. Five out of five major pharma and biotech companies increased their R&D spending this year compared to the previous year. The top pharmaceutical companies in terms of sales have been investing heavily in R&D to devel
